|
|
9. Innovations in Managing
Diabetes Through the Lifecycle Sunday,
September 17, 2000
09:00 - 17:10
| a.
Insulin
Resistance: Today and Tomorrow |
| 09:00-09:10 |
Welcome
Meng H. Tan, Medical Director, Diabetes Care, Eli Lilly and Company,
USA |
| 09:10-09:20 |
Opening Remarks: Morning
Co-chairperson:
Yoram Kanter, Rambam Medical Center, Haifa, Israel |
| 09:20-09:55 |
Insulin Resistance - the Core Defect in Type 2 Diabetes?
Leif C. Groop, University of Lund, Malmo University Hospital, Malm?,
Sweden |
| 09:55-10:25 |
Coffee Break |
| 10:25-11:00 |
Cardiovascular Disease and Insulin Resistance - the Odd
Couple?
Rafael Carmena, University Hospital, Valencia, Spain |
| 11:00-11:35 |
Therapy for Insulin Resistance - Today and Tomorrow
Robert S. Sherwin, Yale University School of Medicine, New Haven, CT,
USA |
| 11:35-11:45 |
Morning Summary
Co-chairperson:
R?diger Landgraf, Munich University Clinic, Munich, Germany |
| 11:45-13:15 |
Lunch Break |
| b.
Decade of Experience with Humalog: Realizing the Advantages of a Rapid
Acting Insulin |
| 13:15-13:20 |
Greetings
Kathleen S. Wishner, Medical Director, Diabetes Care, Eli Lilly and
Company, USA |
| 13:20-13:30 |
Opening Remarks: Afternoon
Co-chairperson:
Yoram Kanter, Rambam Medical Center, Haifa, Israel |
| 13:30-14:00 |
Humalog: Designing a Rapid Acting Insulin Analog
Richard D. DiMarchi, Group Vice President, Research Technologies and
Product Development, Eli Lilly and Company, USA |
| 14:00-14:30 |
Unlocking the Potential of Humalog in Patients with Type 1
Diabetes
Bernard H. Charbonnel, H?tel Dieu, Orvault, France |
| 14:30-15:00 |
Coffee Break |
| 15:00-15:30 |
Physiologic Treatment with Rapid Acting Insulin Analog in
Patients with Type 2 Diabetes
Stefano Del Prato, University of Padova, Padova, Italy |
| 15:30-16:00 |
Use of Humalog to Minimise the Risk of Hypoglycemia
Brian M, Frier, Royal Infirmary of Edinburgh, Edinburgh, Scotland |
| 16:00-16:30 |
Humalog in Special Circumstances: CSII, Pediatrics,
Pregnancy and Geriatrics
Satish K.Garg, Barbara Davis Center for Childhood Diabetes, University
of Colorado Health Sciences, Denver, CO, USA |
| 16:30-17:00 |
The Advantages of Humalog Mixtures
Hans-Joachim L?ddeke, M?chen-Bogenhausen Clinic, M?chen, Germany |
| 17:00-17:10 |
Closing Remarks
Co-chairperson:
R?diger Landgraf, Munich University Clinic, Munich, Germany |
Jerusalem Hilton Hotel
Yoram Kanter, Israel
Rudiger Landgraf, Germany
Eli Lilly and Company
 FOR
GENERAL ENQUIRIES
Gerald A. Danquist
Scientific Meeting Coordinator
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285, USA
Tel: +1 317 2768590
Fax: +1 317 2778774
E-mail: danquist_gerald_a@lilly.com
FOR
REGISTRATION ENQUIRIES
Jo Widdup, Meeting Manager, Martlet
Blenheim House
120 Church Street
Brighton BN11WH, UK
Tel: + 44 1273-68-68-89
Fax: + 44 1273-57-00-82
E-Mail: jo@martlet.co.uk
|
